Relay Therapeutics has announced the advancement of zovegalisib in combination with atirmociclib and an aromatase inhibitor (AI) into Phase 3 trials for frontline treatment of PI3Kα-mutated, HR+/HER2- metastatic breast cancer. This triplet regimen aims to address the tolerability issues associated with earlier PI3Kα inhibitors, which have limited their use in frontline settings. Initial data from the ongoing ReDiscover study demonstrate a 44% overall response rate (ORR) in heavily pre-treated patients, suggesting that this combination could offer comparable efficacy to current standard-of-care therapies.

The significance of these findings lies in the potential for a well-tolerated, all-oral triplet regimen that could improve patient outcomes in a population with limited treatment options. Zovegalisib, as a pan-mutant selective PI3Kα inhibitor, is designed to minimize toxicity associated with wild-type PI3Kα inhibition, thus enhancing the therapeutic index. The early safety data are promising, with only a 3% discontinuation rate due to treatment-related adverse events and no instances of grade 3 hyperglycemia among pre-diabetic patients. This suggests that the combination may be suitable for long-term use in frontline settings.

The implications for the field are substantial, as this triplet regimen could shift current treatment paradigms for metastatic breast cancer. By potentially offering a more effective and tolerable option, it may accelerate timelines for drug development in this area and encourage further exploration of combination therapies targeting specific mutations. The planned Phase 3 trial, subject to regulatory feedback, is expected to begin in early 2027, marking a critical step in the evolution of precision medicine for breast cancer.

Source: globenewswire.com